These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31994238)

  • 21. An early look at the Organ Procurement and Transplantation Network explant pathology form data.
    Harper AM; Edwards E; Washburn WK; Heimbach J
    Liver Transpl; 2016 Jun; 22(6):757-64. PubMed ID: 26970341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
    Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
    World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation.
    Chen D; Liu S; Chen S; Wang Z; Wu Z; Ma K; Fan J; Peng Z
    Int J Clin Oncol; 2016 Dec; 21(6):1111-1119. PubMed ID: 27368337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection.
    Gan W; Huang JL; Zhang MX; Fu YP; Yi Y; Jing CY; Fan J; Zhou J; Qiu SJ
    J Surg Oncol; 2018 Jun; 117(7):1540-1547. PubMed ID: 29572833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer.
    Grat M; Kornasiewicz O; Hołówko W; Lewandowski Z; Zieniewicz K; Paczek L; Krawczyk M
    Transplant Proc; 2013 Jun; 45(5):1899-903. PubMed ID: 23769067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
    Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS
    J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.
    Bhatti ABH; Naqvi W; Khan NY; Zia HH; Dar FS; Khan ZA; Rana A
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):245-253. PubMed ID: 34117916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer.
    Grąt M; Krasnodębski M; Patkowski W; Wronka KM; Masior Ł; Stypułkowski J; Grąt K; Krawczyk M
    Ann Transplant; 2016 Feb; 21():115-24. PubMed ID: 26887339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recurrence and metastasis of hepatocellular carcinoma after liver transplantation: single center experiences].
    Zheng SS; Chen J; Wang WL; Zhang M; Shen Y; Wu J; Xu X; Yan S
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1609-13. PubMed ID: 19094751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.
    Shimoda M; Ghobrial RM; Carmody IC; Anselmo DM; Farmer DG; Yersiz H; Chen P; Dawson S; Durazo F; Han S; Goldstein LI; Saab S; Hiatt J; Busuttil RW
    Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
    Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
    [No Abstract]   [Full Text] [Related]  

  • 35. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V; Citterio D; Bhoori S; Bongini M; Miceli R; De Carlis L; Colledan M; Salizzoni M; Romagnoli R; Antonelli B; Vivarelli M; Tisone G; Rossi M; Gruttadauria S; Di Sandro S; De Carlis R; Lucà MG; De Giorgio M; Mirabella S; Belli L; Fagiuoli S; Martini S; Iavarone M; Svegliati Baroni G; Angelico M; Ginanni Corradini S; Volpes R; Mariani L; Regalia E; Flores M; Droz Dit Busset M; Sposito C
    Lancet Oncol; 2020 Jul; 21(7):947-956. PubMed ID: 32615109
    [TBL] [Abstract][Full Text] [Related]  

  • 36.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M; Dodge JL; Roberts JP; Terrault N; Yao F; Mehta N
    Ann Hepatol; 2016; 15(4):545-9. PubMed ID: 27236153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.
    Liu B; Teng F; Fu H; Guo WY; Shi XM; Ni ZJ; Gao XG; Ma J; Fu ZR; Ding GS
    BMC Gastroenterol; 2015 Oct; 15():138. PubMed ID: 26472203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.
    Wang J; Bao J; Wang R; Hong J; Zhang L; Que Q; Xu S; Wu Y; Zhan Q; Liu Y; Liu J; Zheng S; Ling S; Xu X
    World J Surg Oncol; 2023 Mar; 21(1):104. PubMed ID: 36967432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.